Tourmaline Bio (TRML) News Today

Tourmaline Bio, Inc. (NASDAQ: TRML) shares are trading higher today following confirmation that Novartis AG will acquire the company for $1.4 billion in cash at $48.00 per share, representing a substantial premium to prior levels. Analyst actions and shareholder lawsuits are also drawing investor attention.

• Positive Sentiment: Novartis to acquire Tourmaline for $1.4 billion in cash at $48.00 per share, a 59% premium to the last closing price, bolstering near-term shareholder value. Reuters
• Positive Sentiment: The deal highlights the strategic value of pacibekitug—a late-stage anti-IL-6 monoclonal antibody for cardiovascular inflammation—complementing Novartis’s heart-drug pipeline. Yahoo Finance
• Neutral Sentiment: Wedbush reaffirmed a “Neutral” rating on TRML with a $48.00 price target, implying roughly 0.9% upside from current levels. Benzinga TickerReport
• Negative Sentiment: Halper Sadeh LLC is investigating whether the $48 per-share sale to Novartis is fair to Tourmaline shareholders, introducing potential legal overhang. Business Wire
• Negative Sentiment: The Ademi Firm opened a shareholder probe into possible fiduciary-duty breaches over Tourmaline’s sale process, adding scrutiny to the transaction. Business Wire